Skip to main navigation

Contact Us
Join Us
LinkedIn

Our Company
Our Commitment
Our Innovation
Investors and Media
- Column
- Column

Our Company
Our Commitment
Our Innovation
Investors and Media
- Column
- Column

Event Details

Overview
Stock
News
Events
Governance
SEC Filings
Disclosures
FAQs
Resources
Extra menu
Extra menu
Extra menu

Overview
Stock
News
Events
Governance
SEC Filings
Disclosures
FAQs
Resources
Extra menu
Extra menu
Extra menu

RELIEF Phase 2b Topline Readout Webcast

Jun 10, 2024

Supporting Materials

RELIEF Phase 2b Topline Readout Presentation 2.4 MB

Rethinking Ophthalmology

Our Company
About Us
Our Team
Our Culture
Contact Us
Join Us
LinkedIn

Our Commitment
Diabetic Macular Edema I OCS-01
Post Ocular Surgery I OCS-01
Dry Eye Disease I OCS-02
Uveitis ׀ OCS-02
Acute Optic Neuritis ׀ OCS-05

Our Innovation
Pipeline
Clinical Trials
Science
Publications

Investors and Media
Overview
Stock Information
News Releases
Events & Presentations
Corporate Governance
SEC Filings
Public Disclosures
Investor FAQs
Investor Resources

© 2024 Oculis All Rights Reserved

Terms of Use
Privacy Notice
Cookie Policy
Expanded Access Policy